In a report issued on September 12, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $27.00. The company’s shares closed last Monday at $11.12, close to its 52-week low of $10.22.
According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.7% and a 33.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.50, which is a 158.7% upside from current levels. In a report issued on September 8, Guggenheim also initiated coverage with a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.26 and a one-year low of $10.22. Currently, Aerie Pharma has an average volume of 708K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.